Clinical study to evaluate the safety and tolerability of immunoglobulin intravenous (human) 10% (NewGam) administered at high infusion rates to patients with primary immunodeficiency diseases

Submission date 08/03/2011	Recruitment status No longer recruiting	 Prospectively registered Protocol
Registration date 16/03/2011	Overall study status Completed	 [] Statistical analysis plan [X] Results
Last Edited 15/03/2019	Condition category Other	Individual participant data

Plain English summary of protocol

Background and study aims

This study aims to find a treatment for Primary Immunodeficiency Diseases (PID). According to the leading experts in immunology, when part of the immune system (body mechanism that protects the body against infection caused by bacteria, viruses, fungi or parasites) is either absent or not functioning properly, it can result in an immune deficiency disease. When the cause of this deficiency is hereditary or genetic, it is called a primary immunodeficiency disease (PID). One of the most common signs of PID is an increased susceptibility to infections. You may have infections that are more frequent, longer lasting or harder to treat than are the infections of someone with a normal immune system. You may also get infections that a person with a healthy immune system likely wouldn't get (called opportunistic infections).

One of the common treatments for PID is Immunoglobulin therapy. Immunoglobulin consists of antibody proteins needed for the immune system to fight infections. It can be injected into a vein through an intravenous (IV) line. Treatment with IV immunoglobulin is needed every few weeks to maintain sufficient levels of antibodies in your blood.

Who can participate?

You may only participate in the NGAM-05 study if you completed the NGAM-01 study and did not notice any side effects during your last few IV immunoglobulin infusions of that study.

What does the study Involve?

This study, named NGAM-05, is an extension of the NGAM-01 study that was testing a new formulation of IV Immunoglobulin called NewGam. In the NGAM-05 study we are testing the same NewGam and you will receive the same dose as in NGAM-01. The difference is that the NewGam is given to you at a faster speed and during a shorter time than the usual medicine is given to you. You will receive either four infusions if on a 4 week infusion schedule, or five infusions if on a 3-week infusion schedule, and a follow-up visit.

What are the possible benefits and risks of participating?

The benefit of being in this study is that your infusions will go faster than normal, and your visit to the doctors office will take less time than normal.

The risks of being in this study are that you may experience more side effects than normal. It is felt that the faster you get the medicine, usually the risk of side effects goes up. The most common side effects when people take IV immunoglobulin are headache, chills, migraine, dizziness, fever, nausea/vomiting, fatigue, faster heart rate, Itching, upper abdominal pain, rash /hives, increased blood pressure and cough.

Where is the study run from? This study is being run at six different centers in the USA.

When is the study starting and how long is it expected to run for? This study started in May 2011 and is expected to last until September 2012.

Who is funding the study? Octapharma.

Who is the main contact? Barbara Pyringer barbara.pyringer@octapharma.com

Contact information

Type(s) Scientific

Contact name Dr Wolfgang Frenzel

Contact details

Oberlaaer Str. 235 Vienna Austria 1100

Additional identifiers

EudraCT/CTIS number 2011-005015-82

IRAS number

ClinicalTrials.gov number NCT01313507

Secondary identifying numbers NGAM-05 (extension of study NGAM 01)

Study information

Scientific Title

Clinical study to evaluate the safety and tolerability of immunoglobulin intravenous (human) 10% (NewGam) administered at high infusion rates to patients with primary immunodeficiency diseases: a prospective, open label, non-controlled, non-randomised, multicentre, phase III study

Study objectives

To assess the safety and tolerability of NewGam when administered at infusion rates from 0.08 mL/kg/min to 0.14 mL/kg/min

Extension of study NGAM 01 registered under http://www.controlled-trials.com /ISRCTN05425999

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Research and Clinical Trials Administration Office, Rush University Medical Parkway, approval granted on 04/03/2011

2. Western IRB, approval granted on 16/03/2011

3. St. Louis University Biomedical Institutional Review Board, approval granted on 05/04/2011

4. Institutional Review board, Seattle Childrens Hospital, approval granted on 22/12/2011

5. Office of Research Administration, University of California Irvine, approval granted on 08/04 /2011

Study design

Prospective open-label non-controlled non-randomised multicentre Phase III study

Primary study design

Interventional

Secondary study design

Other

Study setting(s) Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Primary immunodeficiency (PID) diseases

Interventions

Patients will receive NewGam every 3 or 4 weeks (+/-3 days) following the same dosing interval as in the main study NGAM 01. Patients who complete the present study will receive either 5 (at 3-week intervals) or 4 (at 4-week intervals) infusions of NewGam.

Intervention Type

Other

Phase

Phase III

Primary outcome measure

- 1. Occurrence of adverse events (AEs)
- 2. Occurrence of AEs temporally associated with the study treatment
- 3. Proportion of infusions with one or more temporally associated AEs
- 4. AEs by infusion rate

5. Short-term tolerance parameters including vital signs (blood pressure, heart rate,

temperature, respiratory rate)

6. Laboratory parameters (haematology, clinical chemistry, direct Coombs' test, urinalysis, and tests for viral safety)

Secondary outcome measures

Quality of Life:

For QoL assessments, each patient will continue using the same questionnaire as before. That is, the parent or guardian of patients who were below 14 years of age when they entered the main study NGAM 01 will continue using the Child Health Questionnaire-Parent Form (CHQ-PF50), and patients who were ≥ 14 years of age when they entered the main study will continue using the SF-36 Health Survey

Overall study start date

15/03/2011

Completion date

30/06/2012

Eligibility

Key inclusion criteria

1. Completion of the main study NGAM 01

 At each of the last three infusions in the main study NGAM 01, administration of NewGam at the maximum infusion rate of 0.08 mL/kg/min and without the need for premedication
 For adult patients: freely given written informed consent. For patients below the legal age of majority: freely given written informed consent from parents/legal guardians and written informed assent from the child/adolescent in accordance with the applicable approvals
 For female patients of child-bearing potential, a negative result in a urine pregnancy test conducted at the screening visit

5. Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study

Participant type(s) Patient

Age group Adult **Sex** Both

Target number of participants

20-35

Key exclusion criteria

1. Any condition or circumstance that would have led to the exclusion of the subject from the NGAM 01 study

2. Administration of any immunoglobulin infusion other than NewGam between conclusion of the NGAM 01 study and the beginning of the present study

3. A deviation of the subjects treatment interval of more than 7 days between the last infusion of NewGam in the NGAM 01 study and the first infusion of NewGam in the present study

Date of first enrolment

15/03/2011

Date of final enrolment 30/06/2012

Locations

Countries of recruitment Austria

United States of America

Study participating centre Oberlaaer Str. 235 Vienna Austria

Sponsor information

Organisation Octapharma AG (Switzerland)

Sponsor details Seidenstrasse 2

Lachen Switzerland 8853

1100

Sponsor type

Industry

ROR https://ror.org/002k5fe57

Funder(s)

Funder type Industry

Funder Name Octapharma AG (Switzerland)

Results and Publications

Publication and dissemination plan Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Basic results</u>				No	No
Basic results				No	No